AD		

Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme 1 Polymorphisms and Prognosis among Women Treated with Breast Cancer

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.

Kristin E. Anderson, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota

Minneapolis, MN 55455-2070

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050407 142

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Machanism and Reports and Reports and Reports and Reports Parlied (ROM-0.188). Washington

	ect (0704-0188), Washington, DC 20503			
1. AGENCY USE ONLY	2. REPORT DATE	3. REPORT TYPE AND		-
(Leave blank)	October 2004	Annual (28 Sep	2003 - 27	Sep 2004)
4. TITLE AND SUBTITLE			5. FUNDING N	UMBERS
Metabolizing Enzyme 1 Po	lymorphisms and Progn	osis among	DAMD17-01-	-1-0128
Women Treated with Breas		_		
6. AUTHOR(S)				
Carol Sweeney, Ph.D.				
Kristin E. Anderson, Ph.	D.			
7. PERFORMING ORGANIZATION NAM	ME(S) AND ADDRESS(ES)		8. PERFORMING	G ORGANIZATION
University of Minnesota			REPORT NUMBER	
Minneapolis, MN 55455-2	070			
E-Mail: csweeney@hrc.utah	.edu			
9. SPONSORING / MONITORING			10. SPONSORII	NG / MONITORING
AGENCY NAME(S) AND ADDRESS	(ES)			EPORT NUMBER
U.S. Army Medical Resear	ch and Materiel Comma	nd		
Fort Detrick, Maryland		iiu ·		
Fort Detrick, Maryland	21/02-5012			
11. SUPPLEMENTARY NOTES			<u> </u>	
12a DISTRIBITION / AVAILABILITY S	STATEMENT			12h DISTRIBUTION CODE
12a. DISTRIBUTION / AVAILABILITY S		imited		12b. DISTRIBUTION CODE
12a. DISTRIBUTION / AVAILABILITY S Approved for Public Rele		imited		12b. DISTRIBUTION CODE
Approved for Public Rele	ase; Distribution Unl	imited		12b. DISTRIBUTION CODE
	ase; Distribution Unl	imited		12b. DISTRIBUTION CODE
Approved for Public Rele	ase; Distribution Unl	imited		12b. DISTRIBUTION CODE
Approved for Public Rele 13. ABSTRACT (Maximum 200 Words	ase; Distribution Unl		of woman tr	
Approved for Public Rele 13. ABSTRACT (Maximum 200 Words This study uses archived	ase; Distribution Unl	xamine survival		eated for breast
Approved for Public Rele 13. ABSTRACT (Maximum 200 Words This study uses archived cancer in relation to in	d tissue and data to enherited polymorphisms	xamine survival of drug metabol	lizing enzym	eated for breast
Approved for Public Rele 13. ABSTRACT (Maximum 200 Words This study uses archived cancer in relation to in 3, we have completed re-	d tissue and data to enherited polymorphisms view of over 750 poten	xamine survival of drug metabol tially eligible	lizing enzym cases and h	ceated for breast nes. During year nave collected
Approved for Public Rele 13. ABSTRACT (Maximum 200 Words This study uses archived cancer in relation to in 3, we have completed retissue blocks for over	d tissue and data to enherited polymorphisms view of over 750 poten 400, so that collection	xamine survival of drug metabol tially eligible n of tissue samp	lizing enzyn cases and h oles (SOW Ta	reated for breast nes. During year nave collected nsk 2) is almost
This study uses archived cancer in relation to in 3, we have completed retissue blocks for over complete. We have obtain	d tissue and data to enherited polymorphisms view of over 750 poten 400, so that collectionined updated vital star	xamine survival of drug metabol tially eligible n of tissue samp tus and cause of	lizing enzym cases and h bles (SOW Ta death info	reated for breast nes. During year nave collected nsk 2) is almost prmation for
This study uses archived cancer in relation to in 3, we have completed retissue blocks for over complete. We have obtained in the subjects. And the subjects is the subjects of the subject of the subjects of the subject of the su	d tissue and data to enherited polymorphisms view of over 750 poten 400, so that collectionined updated vital statestension of the projections.	xamine survival of drug metabol tially eligible n of tissue samp tus and cause of	lizing enzym cases and h bles (SOW Ta death info n year has h	reated for breast nes. During year nave collected nsk 2) is almost prmation for neen approved.
This study uses archived cancer in relation to in 3, we have completed retissue blocks for over complete. We have obtain	d tissue and data to enherited polymorphisms view of over 750 poten 400, so that collectionined updated vital statestension of the projectect genotypes and tume	xamine survival of drug metabol tially eligible n of tissue samp tus and cause of ct into a fourth or markers will	lizing enzym cases and holes (SOW Ta death info n year has hole conducte	reated for breast nes. During year nave collected nsk 2) is almost prmation for neen approved.

14. SUBJECT TERMS			15. NUMBER OF PAGES 8
Breast Cancer			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments	7
Reportable Outcomes	7
Conclusions	7
References	8
Appendices	N/A

INTRODUCTION

This study uses archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. We had reported from a pilot study that carrying the homozygous genotype for the glutathione S-transferase (GST)P1 Val¹⁰⁵ variant, associated with lower enzymes activity toward alkylating agents, or the homozygous genotype for GSTA1*B, a promoter variant that reduces hepatic expression of GSTA1, predicted improved overall among women treated for breast cancer (1, 2). The present, DOD-funded study, extends this area of research to a larger population of women treated for breast cancer and will consider whether these associations are independent of other prognostic markers in tumor tissue. The study design is a retrospective cohort; subject who received first course of therapy for invasive, primary breast cancer at an academic medical center have been identified through the hospital tumor registry. Archived pathological tissue blocks for these women will be the source of tissue for laboratory assays. Genotypes will be determined from normal DNA, and prognostic markers will be evaluated by immunohistochemistry. We will evaluate associations between genotypes and recurrence and overall survival, taking into account other prognostic markers.

BODY

The Statement of Work identified five tasks, as follows:

- Task 1. Compilation of Data for Eligible Subjects
- Task 2. Archived Tissue Specimens Obtained
- Task 3. DNA Extraction and Genotyping
- Task 4. Immunohistochemistry
- Task 5. Data Analysis and Report Writing

Task 1 was completed during the first year of funding.

Task 2 was initiated during year 2.

During year 3, we have proceeded with Task 2, collecting tissue samples. A total of 771 potentially eligible cases from 3 hospitals were identified by the Fairview University Medical Centers (FUMC) tumor registry have been reviewed by the study coordinator. Of these cases, over 200 could not be included because pathology records and/or tissue could not be obtained (Table 1).

Table 1. Summary of potentially eligible breast cancer cases reviewed

Outcome	Number
Ineligible	
No pathology reports exists in FUMC system	80
In situ disease only	5
No tissue available	
No tissue blocks available	136
Core biopsy tissue only	32
In process	
Requesting slides/blocks	35
Need further review of pathology	23
Completed	
Review complete, blocks obtained	460

For the remaining cases, except for those in process (requesting pathological material) or requiring further review, the study pathologist has reviewed slides and, if the case was eligible on pathological crieria, has selected a normal lymph node block for DNA extraction and a block containing representative tumor tissue for immunohistochemical staining. Tissue sections are have been cut and mounted on slides for over 400 of the cases obtained to date so that material is ready and laboratory assays for Tasks 3 and 4 will start soon.

During year 3 we have obtained updated vital status and cause of death information for eligible subjects through linkage with electronic Minnesota death certificate records.

Unexpected obstacles have been encountered during data collection, resulting in slower progress than what was outlined the original statement of work. A primary problem has been that the proportion of potentially eligible cases with no pathology record in the FUMC system, or no tissue blocks available, is larger than anticipated. Therefore it was not possible to collect samples for an adequate number of study subjects from one hospital as had been originally planned. We expanded the study to several hospitals within the FUMC system in order to accrue a sufficient number of samples. Working with additional hospitals, however, created the necessity of submitting, and waiting for approval of, revisions to IRB the protocols. To work with more hospitals we also needed to hire and train additional part-time personnel. This additional administrative workload on the PI and study coordinator contributed to slower-than-anticipated progress during year 2 and the early part of year 3. Substantial progress has been made during the balance of year 3, and an extension of the project period into year 4 has been approved. At present, in October, 2004, progress on the research has been

slowed while we wait for a response from the DOD IRB to a protocol revision submitted in April, 2004, which included addition of one more FUMC hospital as a source of tissue for the study. If approval of this revision is not received soon, the project will fall further behind schedule and we will not be able to increase the sample size to what was originally planned.

KEY RESEARCH ACCOMPLISHMENTS

Tasks 3, 4, and 5 are yet to be completed. Laboratory assays for genotypes and pathological markers will be underway shortly. No reportable scientific results will be available until these tasks are complete. The PI presented a poster describing study methods and rationale at the "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

REPORTABLE OUTCOMES

Abstract

Sweeney C, Gulbahce HE, Coles BF. Metabolizing enzyme polymorphisms and prognosis among women treated for breast cancer. "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 26-28, 2002.

CONCLUSIONS

Data collection tasks are ongoing, so no reportable scientific results are available to date.

REFERENCES

- Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000;60:5621-5624.
- Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione Stransferase A1 promoter polymorphism and survival after breast cancer treatment.
 Int J Cancer 2003;103:810-4.

APPENDICES

N/A